Patients with untreated (i.e., have not started first-line chemotherapy), advanced-stage NSCLC with a sensitizing EGFR mutation (known prior to the initiation of treatment) should start treatment with an oral EFGR TKI (afatinib [Gilotrif], erlotinib, or gefitinib; NCCN, 2016). Here, EGFR is linked to non-small cell lung carcinoma.